A retrospective multi-center study, ALICE-1 (Angiogenesis Liver CancEr), was aimed at evaluating VEGF and VEGFR polymorphisms in determining sorafenib treatment outcome in HCC patients [43]. Here, VEGFA is linked to hepatocellular carcinoma.